| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Femasys Inc.
13D
FEMY · 31447E204
|
10.0% |
8/17/2026
Event 8/10/2026
|
||||
| Nantahala Capital Partners Limited Partnership | 10.0% | |||||
| Nantahala Capital Management, LLC | 10.0% | |||||
| Wilmot B. Harkey | 10.0% | |||||
| Daniel Mack | 10.0% | |||||
| Schedule 13G · 11 securities · passive | ||||||
|
Azitra, Inc.
13G
AZTR · 05479L302
|
8.4% |
8/14/2026
Event 6/30/2026
|
||||
|
Abeona Therapeutics Inc.
13G/A
ABEO · 00289Y206
|
5.8% |
5/15/2026
Event 3/31/2026
|
||||
|
Kiora Pharmaceuticals, Inc.
13G/A
KPRX · 49721T507
|
3.4% |
5/15/2026
Event 3/31/2026
|
||||
|
Curis, Inc.
13G
CRIS · 231269309
|
7.0% |
4/7/2026
Event 3/31/2026
|
||||
|
InspireMD, Inc.
13G/A
NSPR · 45779A846
|
5.7% |
11/14/2025
Event 9/30/2025
|
||||
|
DarioHealth Corp.
13G/A
DRIO · 23725P308
|
4.6% |
11/14/2025
Event 9/30/2025
|
||||
|
Senti Biosciences, Inc.
13G/A
SNTI · 81726A209
|
1.9% |
5/15/2025
Event 3/31/2025
|
||||
|
Surrozen, Inc./DE
13G/A
SRZN · 86889P208
|
2.2% |
5/15/2025
Event 3/31/2025
|
||||
|
DarioHealth Corp.
13G
DRIO · 23725P209
Amended
under CUSIP
23725P308
on 11/14/2025
|
5.8% |
3/6/2025
Event 2/27/2025
|
||||
|
Eagle Pharmaceuticals, Inc.
13G
EGRX · 269796108
|
6.2% |
2/19/2025
Event 2/16/2025
|
||||
| Nantahala Capital Partners Limited Partnership | 6.2% | |||||
| Wilmot B. Harkey | 6.2% | |||||
| Daniel Mack | 6.2% | |||||
|
Unicycive Therapeutics, Inc.
13G/A
UNCY · 90466Y103
|
2.8% |
12/20/2024
Event 12/19/2024
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.